Recombinant proteins

  • Recombinant FVIII is for replacement of coagulation factor FVIII therapy in Hemophilia A boys.
  • After the epidermic where there were transmission of HIV, Hepatitis B and Hepatitis C in the late 1970’s and early 1980’s caused by the use of non–virally inactivated clotting factor concentrates derived from plasma, the need for safer haemophilia treatments became crucial to the haemophilia community.
  • The introduction of recombinant FVIII products dramatically improved the quality of life of patients with haemophilia A and their families and enabled regular infusion of factor concentrate replacement therapy to prevent bleeding and resultant joint damage (i.e., primary prophylaxis), home treatment, and, ultimately, a near-normal lifestyle and life expectancy.